You are here: Industry Insights > Takeda

News List

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases pharmafocusasia
March 21, 2019
HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver diseases, including nonalcoholi
Takeda’s Entyvio bests AbbVie’s Humira in ulcerative colitis trial pharmatimes
March 12, 2019
In the Phase III VARSITY trial, Entyvio (vedolizumab) was found to be superior to Humira (adalimumab) in achieving statistically significant clinical remission at week 52 in patients with moderately to severely active ulcerative colitis.
Takeda, Microsoft rare disease partnership publishes diagnosis road map fiercepharma
March 03, 2019
Now that Takeda has swallowed Shire, it's doubling down on rare disease. And one way it's doing that is through a partnership with Microsoft and Eurodis, which has delivered a road map to shorten time to diagnosis and detailed three pilot programs underwa
Takeda ordered to pay Bayer $155M for hemophilia patent infringement fiercepharma
February 24, 2019
It may not be what Takeda bargained for with its massive Shire buyout, but early into its ownership of the rare disease specialist, a jury ordered the Japanese drugmaker to pay hemophilia rival Bayer $155 million for patent infringement.
Takeda hits FDA snag on Ninlaro, but its growth still helps drive revenue hike fiercepharma
February 24, 2019
In Takeda’s last quarterly report as a separate company from Shire, things seem to be going its way—key drugs are growing nicely, Shire integration is on track, and cash-raising sell-offs are underway, executives said.
University of Dundee and Takeda partner on tau pathology-focused drug development pharmaceutical-technology
February 21, 2019
The University of Dundee Drug Discovery Unit has announced it has entered into a drug development partnership focused on tau pathology with Japanese pharmaceutical giant Takeda.....
NICE backs Takeda’s Alunbrig in second-line lung cancer pharmaceutical-technology
February 20, 2019
The UK’s pricing regulator the National Institute of Health and Care Excellence (NICE) has revised its previous rejection of Takeda’s Alunbrig (brigatinib) for adults with anaplastic lymphoma kinase ....
NICE backs Takeda’s Alunbrig in second-line lung cancer pharmaphorum
February 18, 2019
NICE has published final draft guidance recommending regular NHS funding in England for Takeda’s Alunbrig (brigatinib), for ALK-positive advanced non-small cell lung cancer, in patients already treated with Pfizer’s Xalkori.
EC expands Takeda’s Adcetris authorisation for Hodgkin lymphoma pharmaceutical-technology
February 14, 2019
The European Commission (EC) has expanded the marketing authorisation of Takeda Pharmaceutical’s Adcetris (brentuximab vedotin) to adults with previously untreated CD30+ Stage IV Hodgkin lymphoma....
Takeda hits FDA snag on Ninlaro, but its growth still helps drive revenue hike fiercepharma
February 02, 2019
In Takeda’s last quarterly report as a separate company from Shire, things seem to be going its way—key drugs are growing nicely, Shire integration is on track, and cash-raising sell-offs are underway, executives said.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page